Ignite Creation Date:
2025-12-25 @ 3:33 AM
Ignite Modification Date:
2026-02-23 @ 12:23 PM
Study NCT ID:
NCT02606305
Status:
COMPLETED
Last Update Posted:
2024-06-14
First Post:
2015-11-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRĪ±) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor:
ImmunoGen, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
IMGN853-0402
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None